Clinical Research Directory

Inclusion Criteria: 1. Adult patients aged 18 years or older. 2. Active pulmonary tuberculosis confirmed by positive acid-fast bacilli (AFB) sputum smear or positive molecular rapid test (GeneXpert/TCM), diagnosed by a pulmonologist. 3. Currently undergoing the intensive phase of anti-tuberculosis therapy (ATT), with the duration of ATT treatment less than 14 days since initiation at the time of recruitment. 4. Patients with vitamin D deficiency or insufficiency and zinc deficiency. 5. Patient is willing to follow all study procedures for 8 weeks and signed the written informed consent. 6. Patients who have not consumed vitamin D and/or zinc supplements within the last 30 days (wash-out period). Exclusion Criteria: 1. Patients with extra-pulmonary tuberculosis without lung involvement, or patients with suspected or confirmed MDR-TB/XDR-TB. 2. Pregnant or breastfeeding women. 3. Patients with diseases or conditions that alter vitamin D or calcium metabolism, such as hypercalcemia (total calcium \>= 10.5 mg/dL), hyperparathyroidism, or a history of recurrent calcium nephrolitiasis. 4. Severe liver failure or end-stage renal disease requiring chronic dialysis. 5. Patients taking systemic immunosuppressive drugs (e.g., prednisone equivalent \>10 mg/day for \>= 14 days), active chemotherapy, or active unstable autoimmune disease. 6. Patients with severe uncontrolled co-infections (e.g., sepsis, severe non-TB pneumonia) at the time of screening. 7. Patients with known allergy or hypersensitivity to cholecalciferol or zinc preparations used in this study. 8. Patients unable to follow the follow-up schedules or considered likely to drop out based on investigator's assessment.